Le Rhun E, Taillibert S, Chamberlain M. Neoplastic meningitis due to lung, breast, and melanoma metastases. Cancer Control. 2017;24(1):22–32.

Article  PubMed  Google Scholar 

Morikawa A, Jordan L, Rozner R, Patil S, Boire A, Pentsova E, et al. Characteristics and outcomes of patients with breast cancer with leptomeningeal metastasis. Clin Breast Cancer. 2017;17(1):23–8.

Article  PubMed  Google Scholar 

Gauthier H, Guilhaume MN, Bidard FC, Pierga JY, Girre V, Cottu PH, et al. Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol. 2010;21(11):2183–7.

Article  CAS  PubMed  Google Scholar 

de Azevedo CR, Cruz MR, Chinen LT, Peres SV, Peterlevitz MA, de Azevedo Pereira AE, et al. Meningeal carcinomatosis in breast cancer: prognostic factors and outcome. J Neurooncol. 2011;104(2):565–72.

Article  PubMed  Google Scholar 

Boire A, Zou Y, Shieh J, Macalinao DG, Pentsova E, Massague J. Complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis. Cell. 2017;168(6):1101–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Remsik J, Chi Y, Tong X, Sener U, Derderian C, Park A, et al. Leptomeningeal metastatic cells adopt two phenotypic states. Cancer Rep (Hoboken). 2020;5:e1236.

Article  PubMed  PubMed Central  Google Scholar 

Chi Y, Remsik J, Kiseliovas V, Derderian C, Sener U, Alghader M, et al. Cancer cells deploy lipocalin-2 to collect limiting iron in leptomeningeal metastasis. Science. 2020;369(6501):276–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harris P, Diouf A, Guilbert F, Ameur F, Letourneau-Guillon L, Ménard C, et al. Diagnostic reliability of leptomeningeal disease using magnetic resonance imaging. Cureus. 2019;11(4): e4416.

PubMed  PubMed Central  Google Scholar 

Lardinois B, Miller L, Randazzo A, Laurent T, Debois R, Henry S. Leptomeningeal carcinomatosis: a call for optimizing diagnostic sensitivity by the hematology laboratory. Case Rep Oncol. 2021;14(2):1248–53.

Article  PubMed  PubMed Central  Google Scholar 

Boire A, Brandsma D, Brastianos PK, Le Rhun E, Ahluwalia M, Junck L, et al. Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. Neuro Oncol. 2019;21(5):571–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22(14):2865–72.

Article  PubMed  Google Scholar 

Yust-Katz S, Garciarena P, Liu D, Yuan Y, Ibrahim N, Yerushalmi R, et al. Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis. J Neurooncol. 2013;114(2):229–35.

Article  CAS  PubMed  Google Scholar 

Plasilova ML, Hayse B, Killelea BK, Horowitz NR, Chagpar AB, Lannin DR. Features of triple-negative breast cancer: Analysis of 38,813 cases from the national cancer database. Medicine (Baltimore). 2016;95(35): e4614.

Article  PubMed  Google Scholar 

Scott BJ, Oberheim-Bush NA, Kesari S. Leptomeningeal metastasis in breast cancer: a systematic review. Oncotarget. 2016;7(4):3740–7.

Article  PubMed  Google Scholar 

Brouckaert O, Rudolph A, Laenen A, Keeman R, Bolla MK, Wang Q, et al. Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. Breast Cancer Res. 2017;19(1):119.

Article  PubMed  PubMed Central  Google Scholar 

Franzoi MA, Hortobagyi GN. Leptomeningeal carcinomatosis in patients with breast cancer. Crit Rev Oncol Hematol. 2019;135:85–94.

Article  PubMed  Google Scholar 

Winters S, Martin C, Murphy D, Shokar NK. Breast cancer epidemiology, prevention, and screening. Prog Mol Biol Transl Sci. 2017;151:1–32.

Article  CAS  PubMed  Google Scholar 

Johnson HM, Irish W, Vohra NA, Wong JH. Refining breast cancer prognosis by incorporating age at diagnosis into clinical prognostic staging: introduction of a novel online calculator. Breast Cancer Res Treat. 2021;187(3):805–14.

Article  PubMed  Google Scholar 

Song QK, Li J, Huang R, Fan JH, Zheng RS, Zhang BN, et al. Age of diagnosis of breast cancer in china: almost 10 years earlier than in the United States and the European union. Asian Pac J Cancer Prev. 2014;15(22):10021–5.

Article  PubMed  Google Scholar 

Frank S, Carton M, Dubot C, Campone M, Pistilli B, Dalenc F, et al. Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort. Breast. 2020;52:50–7.

Article  PubMed  PubMed Central  Google Scholar 

Le Rhun E, Weller M, Brandsma D, Van den Bent M, de Azambuja E, Henriksson R, et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol. 2017;28(suppl_4):iv84–99.

Article  PubMed  Google Scholar 

Maajani K, Jalali A, Alipour S, Khodadost M, Tohidinik HR, Yazdani K. The global and regional survival rate of women with breast cancer: a systematic review and meta-analysis. Clin Breast Cancer. 2019;19(3):165–77.

Article  PubMed  Google Scholar 

Berghoff A, Bago-Horvath Z, De Vries C, Dubsky P, Pluschnig U, Rudas M, et al. Brain metastases free survival differs between breast cancer subtypes. Br J Cancer. 2012;106(3):440–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ahn HK, Park YH, Lee SJ, Park S, Maeng CH, Park W, et al. Clinical implication of Time To Brain Metastasis (TTBM) according to breast cancer subtypes. Springerplus. 2013;2(1):136.

Article  PubMed  PubMed Central  Google Scholar 

Torrejón D, Oliveira M, Cortes J, Sanchez-Olle G, Gómez P, Bellet M, et al. Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis. Breast. 2013;22(1):19–23.

Article  PubMed  Google Scholar 

Figura NB, Rizk VT, Mohammadi H, Evernden B, Mokhtari S, Yu HM, et al. Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy. Breast Cancer Res Treat. 2019;175(3):781–8.

Article  CAS  PubMed  Google Scholar 

Lamba N, Cagney DN, Catalano PJ, Elhalawani H, Haas-Kogan DA, Wen PY, et al. Genomic Predictors of Leptomeningeal Disease Development among Patients with Brain Metastases. Int J Radiat Oncol Biol Phys. 2023;117(2, Supplement):S76.

Article  Google Scholar 

Abouharb S, Ensor J, Loghin ME, Katz R, Moulder SL, Esteva FJ, et al. Leptomeningeal disease and breast cancer: the importance of tumor subtype. Breast Cancer Res Treat. 2014;146(3):477–86.

Article  CAS  PubMed  Google Scholar 

Mills MN, Walker C, Thawani C, Naz A, Figura NB, Kushchayev S, et al. Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases. BMC Cancer. 2021;21(1):223.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast. 2006;15(2):219–25.

Article  CAS  PubMed  Google Scholar 

Bowman KM, Kumthekar P. Medical management of brain metastases and leptomeningeal disease in patients with breast carcinoma. Future Oncol. 2018;14(4):391–407.

Article  CAS  PubMed  Google Scholar 

Bonneau C, Paintaud G, Trédan O, Dubot C, Desvignes C, Dieras V, et al. Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis. Eur J Cancer. 2018;95:75–84.

Article  CAS  PubMed  Google Scholar 

Mehta M, Bradley K. Radiation therapy for leptomeningeal cancer. Cancer Treat Res. 2005;125:147–58.

Article  PubMed  Google Scholar 

Gamucci T, Pizzuti L, Natoli C, Mentuccia L, Sperduti I, Barba M, et al. A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study Cancer Biol Ther. 2019;20(2):192–200.

Article  CAS  PubMed  Google Scholar 

Vici P, Pizzuti L, Michelotti A, Sperduti I, Natoli C, Mentuccia L, et al. A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. Oncotarget. 2017;8(34):56921–31.

Article  PubMed  PubMed Central  Google Scholar 

Schettini F, Conte B, Buono G, De Placido P, Parola S, Griguolo G, et al. T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study. ESMO Open. 2021;6(2): 100099.

Article  CAS  PubMed  PubMed Central